Literature DB >> 19289395

HER-2 as a target for breast cancer therapy.

Michail Ignatiadis1, Christine Desmedt, Christos Sotiriou, Evandro de Azambuja, Martine Piccart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19289395     DOI： 10.1158/1078-0432.CCR-08-1844

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  14 in total

1.  Breast cancer: Should we assess HER2 status by Oncotype DX?

Authors:  Michail Ignatiadis; Christos Sotiriou
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2+ and ErbB-2- primary breast tumors.

Authors:  Rebeca Sanz-Pamplona; Ramón Aragüés; Keltouma Driouch; Berta Martín; Baldo Oliva; Miguel Gil; Susana Boluda; Pedro L Fernández; Antonio Martínez; Víctor Moreno; Juan J Acebes; Rosette Lidereau; Fabien Reyal; Marc J Van de Vijver; Angels Sierra
Journal:  Am J Pathol       Date:  2011-06-25       Impact factor: 4.307

3.  Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling.

Authors:  Jennifer Chun; Thomas A Zangle; Theodora Kolarova; Richard S Finn; Michael A Teitell; Jason Reed
Journal:  Analyst       Date:  2012-10-11       Impact factor: 4.616

4.  Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

Authors:  Gul Basaran; Cabuk Devrim; Hale B Caglar; Bahadir Gulluoglu; Handan Kaya; Selcuk Seber; Taner Korkmaz; Ferhat Telli; Muharrem Kocak; Faysal Dane; Fulden P Yumuk; Serdar N Turhal
Journal:  Med Oncol       Date:  2011-09       Impact factor: 3.064

Review 5.  Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.

Authors:  Jacek Capala; Kirsten Bouchelouche
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

6.  A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Authors:  Wei Wang; Elizabeth R Rayburn; Sadanandan E Velu; Deng Chen; Dwayaja H Nadkarni; Srinivasan Murugesan; Dongquan Chen; Ruiwen Zhang
Journal:  Breast Cancer Res Treat       Date:  2009-11-21       Impact factor: 4.872

7.  Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor.

Authors:  Peng-Zhou Kong; Fan Yang; Lin Li; Xiao-Qing Li; Yu-Mei Feng
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

8.  Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.

Authors:  C-R Pradeep; W J Köstler; M Lauriola; R Z Granit; F Zhang; J Jacob-Hirsch; G Rechavi; H B Nair; B T Hennessy; A M Gonzalez-Angulo; R R Tekmal; I Ben-Porath; G B Mills; E Domany; Y Yarden
Journal:  Oncogene       Date:  2011-07-11       Impact factor: 9.867

9.  NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth.

Authors:  Keshav Karki; Kumaravel Mohankumar; Abigail Schoeller; Gregory Martin; Rupesh Shrestha; Stephen Safe
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

10.  Molecular imaging probes for diagnosis and therapy evaluation of breast cancer.

Authors:  Qingqing Meng; Zheng Li
Journal:  Int J Biomed Imaging       Date:  2013-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.